Breakthrough science is transforming drug development, but these innovations are meaningless if patients can’t access them. That’s why biopharma companies need to work with other health care stakeholders to develop new ways to pay for medicines, like innovative contracts.
RE has structured, negotiated, and monitored innovative contracts that significantly impact medical policy and utilization
RE offers end-to-end services to support innovative contracts
